Antimicrobial susceptibility/resistance and genetic characteristics of Neisseria gonorrhoeae isolates from Poland, 2010-2012

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Mlynarczyk Bonikowska, Beata ^a   Serwin, Agnieszka B ^b   Golparian, Daniel ^c   Walter de Walthoffen, Szymon ^a   Majewski, Slawomir ^a   Koper, Marta ^b   Malejczyk, Magdalena ^a   Domeika, Marius ^d   Unemo, Magnus ^c  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^c ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^d Smittskyddsenheten   (Sweden)

Author keywords

Antimicrobial resistance (AMR); Cefixime; Ceftriaxone; Extended spectrum cephalosporins (ESCs); Gonorrhoea; Neisseria gonorrhoeae; NG MAST; penA; Poland

Indexed keywords

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; FEMALE; GONORRHEA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEISSERIA GONORRHOEAE; POLAND; PREVALENCE; YOUNG ADULT;

EID: 84893163701     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-65     Document Type: Article

References (47)

1. World Health Organization Global incidence and prevalence of selected curable sexually transmitted infections - 2008 2012, Geneva: World Health Organization, Available at: http://www.who.int/reproductivehealth/publications/rtis/2008_STI_estimates.pdf (Accessed: January 19, 2014), World Health Organization.
2. European Centre for Disease Prevention and Control Sexually Transmitted Infections in Europe 2011 2013, ECDC, Available at: http://www.ecdc.europa.eu/en/publications/publications/sexually-transmitted-infections-europe-2011.pdf (Accessed: January 19, 2014), European Centre for Disease Prevention and Control.
3. Tapsall JW, Ndowa F, Lewis DA, et al. Meeting the public health challenge of multidrug-and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009, 7:821-834. 10.1586/eri.09.63, 19735224.
4. Lewis DA. The gonococcus fights back: is this time a knock out?. Sex Transm Infect 2010, 86:415-421. 10.1136/sti.2010.042648, 20656721.
5. Unemo M, Nicholas RA. Emergence of multi-drug resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012, 7:1401-1422. 10.2217/fmb.12.117, 3629839, 23231489.
6. Tapsall J. Antimicrobial resistance in Neisseria gonorrhoeae. WHO/CDS/DRS/2001.3:16 2001, Geneva: World Health Organisation (WHO).
7. Yokoi S, Deguchi T, Ozawa T, et al. Threat to cefixime treatment for gonorrhea. Emerg Infect Dis 2007, 13:1275-1277. 2828067, 17953118.
8. Ison CA, Hussey J, Sankar KN, et al. Gonorrhoea treatment failures to cefixime and azithromycin in England. Euro Surveill 2011, 16(14). Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19833.
9. Unemo M, Golparian D, Nicholas R, et al. High-level cefixime-and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012, 56:1273-1280. 10.1128/AAC.05760-11, 3294892, 22155830.
10. Unemo M, Golparian D, Stary A, et al. First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Euro Surveill 2011, 16(43). Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19998.
11. Unemo M, Golparian D, Syversen G, et al. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill 2010, 15(47). Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19721.
12. Lewis DA, Sriruttan C, Müller EE, et al. Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrob Chemother 2013, 68:1267-1270. 10.1093/jac/dkt034, 23416957.
13. Allen VG, Mitterni L, Seah C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 2013, 309:163-170. 10.1001/jama.2012.176575, 23299608.
14. Tapsall J, Read P, Carmody C, et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol 2009, 58:683-687. 10.1099/jmm.0.007641-0, 19369534.
15. Unemo M, Golparian D, Hestner A. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill 2011, 16(6). Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19792.
16. Unemo M, Golparian D, Potocnik M, et al. Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011. Euro Surveill 2012, 17(25). Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20200.
17. Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011, 55:3538-3545. 10.1128/AAC.00325-11, 3122416, 21576437.
18. Chen YM, Stevens K, Tideman R, et al. Failure of ceftriaxone 500 mg to eradicate pharyngeal gonorrhoea, Australia. J Antimicrob Chemother 2013, 68:1445-1447. 10.1093/jac/dkt017, 23390207.
19. Cámara J, Serra J, Ayats J, et al. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother 2012, 67:1858-1860. 10.1093/jac/dks162, 22566592.
20. World Health Organization (WHO), Department of Reproductive Health and Research Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae 2012, 1-36. Geneva: WHO, Available at: http://www.who.int/reproductivehealth/publications/rtis/9789241503501 (Accessed: January 19, 2014), World Health Organization (WHO), Department of Reproductive Health and Research.
21. European Centre for Disease Prevention and Control (ECDC) Response plan to control and manage the threat of multidrug-resistant gonorrhoea in Europe 2012, 1-23. Stockholm: ECDC, Available at: http://www.ecdc.europa.eu/en/publications/Publications/1206-ECDC-MDR-gonorrhoea-response-plan.pdf (Accessed: January 19, 2014), European Centre for Disease Prevention and Control (ECDC).
22. Centers for Disease Control and Prevention (CDC) Cephalosporin-resistant Neisseria gonorrhoeae public health response plan 2012, 1-43. CDC, Available at: http://www.cdc.gov/std/treatment/ceph-r-responseplanjuly30-2012.pdf (Accessed: January 19, 2014), Centers for Disease Control and Prevention (CDC).
23. Bignell C, Unemo M, on behalf of the European STI Guidelines Editorial Board European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 2013, 24:85-92. 10.1177/0956462412472837, 24400344, on behalf of the European STI Guidelines Editorial Board.
24. Ameyama S, Onodera S, Takahata M, et al. Mosaic-like structure of penicillin-binding protein 2 gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime. Antimicrob Agents Chemother 2002, 46:3744-3749. 10.1128/AAC.46.12.3744-3749.2002, 132769, 12435671.
25. Ito M, Deguchi T, Mizutani KS, et al. Emergence and spread of Neisseria gonorrhoeae clinical isolates harboring mosaic-like structure of penicillin-binding protein 2 in central Japan. Antimicrob Agents Chemother 2005, 49:137-143. 10.1128/AAC.49.1.137-143.2005, 538884, 15616287.
26. Lee SG, Lee H, Jeong SH, et al. Various penA mutations together with mtrR, porB and ponA mutations in Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime or ceftriaxone. J Antimicrob Chemother 2010, 65:669-675. 10.1093/jac/dkp505, 2837549, 20093260.
27. Osaka K, Takakura T, Narukawa K, et al. Analysis of amino acid sequences of penicillin-binding protein 2 in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime and ceftriaxone. J Infect Chemother 2008, 14:195-203. 10.1007/s10156-008-0610-7, 18574654.
28. Takahata S, Senju N, Osaki Y, et al. Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother 2006, 50:3638-3645. 10.1128/AAC.00626-06, 1635225, 16940068.
29. Tomberg J, Unemo M, Davies C, et al. Molecular and structural analysis of mosaic variants of penicillin-binding protein 2 conferring decreased susceptibility to expanded-spectrum cephalosporins in Neisseria gonorrhoeae: role of epistatic mutations. Biochemistry 2010, 49:8062-8070. 10.1021/bi101167x, 2939205, 20704258.
30. Zhao S, Duncan M, Tomberg J, et al. Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob Agents Chemother 2009, 53:3744-3751. 10.1128/AAC.00304-09, 2737842, 19528266.
31. Unemo M, Dillon JA. Review and international recommendation of methods for typing Neisseria gonorrhoeae isolates and their implications for improved knowledge of gonococcal epidemiology, treatment, and biology. Clin Microbiol Rev 2011, 24:447-458. 10.1128/CMR.00040-10, 3131056, 21734242.
32. Majewski S, Rudnicka I, Dajek Z. Zapalenia cewki moczowej i narza{ogonek}du rodnego in: Poste{ogonek}powanie w przypadku rozpoznania chorób przenoszonych droga{ogonek} płciowa{ogonek}: Czelej 2000, 5-8. Lublin, 1, In Polish.
33. Jablonska S, Majewski S. Choroby przenoszone droga płciowa. Choroby skóry i choroby przenoszone droga{ogonek} plciowa 2010, 457-507. Polish: PZWL Warsaw.
34. Hoffmann B, Monsiorska-Borowska Z, Araszkiewicz M, et al. Assessment of sensitivity to penicillin and other antibiotics in Neisseria gonorrhoeae in Poland in 1973. Pol Tyg Lek 1974, 29:1151-1154. In Polish.
35. Michalska-Trenkner E, Dratwiński Z, Wiewiórkowska L. Drug resistance of Neisseria gonorrhoeae in the Gdansk Province. Przegl Dermatol 1975, 62:377-382. In Polish.
36. Stapinski A, Mroczkowski TF, Dajek Z, et al. 1st cases of gonorrhea caused by penicillinase-producing Neisseria gonorrhoeae in Poland. Przegl Dermatol 1979, 66:487-494. In Polish.
37. Mlynarczyk-Bonikowska B, Przedpelska G, Malejczyk M, et al. Penicillinase production by Neisseria gonorrhoeae strains isolated from the patients of Dermatology and Wenerology Clinic, Warsaw Medical University in 2006-2009. Med Dosw Mikrobiol 2011, 63:115-120. In Polish.
38. Linda H, Dzierzanowska D, Bramska S. Studies on the effectiveness of cephalosporins against Neisseria gonorrhoeae. Przegl Dermatol 1979, 66:685-688. In Polish.
39. Tapsall JW, Cheng JK. Rapid identification of pathogenic species of Neisseria by carbohydrate degradation tests: importance of glucose in media used for preparation of inocula. Br J Ven Dis 1981, 57:249-252.
40. Unemo M, Olcen P, Berglund T, et al. Molecular epidemiology of Neisseria gonorrhoeae: sequence analysis of the porB gene confirms presence of two circulating strains. J Clin Microbiol 2002, 40:3741-3749. 10.1128/JCM.40.10.3741-3749.2002, 130889, 12354874.
41. Unemo M, Fasth O, Fredlund H, et al. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J Antimicrob Chemother 2009, 63:1142-1151. 10.1093/jac/dkp098, 19318360.
42. Martin IM, Ison CA, Aanensen DM, et al. Rapid sequence-based identification of gonococcal transmission clusters in a large metropolitan area. J Infect Dis 2004, 189:1497-1505. 10.1086/383047, 15073688.
43. Unemo M, Olcén P, Fredlund H, et al. Real-time PCR and subsequent pyrosequencing for screening of penA mosaic alleles and prediction of reduced susceptibility to expanded-spectrum cephalosporins in Neisseria gonorrhoeae. APMIS 2008, 116:1004-1008. 10.1111/j.1600-0463.2008.01062.x, 19132998.
44. Deguchi T, Yasuda M, Yokoi S, et al. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J Infect Chemother 2003, 9:35-39. 10.1007/s10156-002-0204-8, 12673405.
45. European Centre for Disease Prevention and Control Gonococcal antimicrobial susceptibility surveillance in Europe-2010 2012, Stockholm: ECDC, Available at: http://www.ecdc.europa.eu/en/publications/publications/1206-gonococcal-amr.pdf (Accessed: January 19, 2014), European Centre for Disease Prevention and Control.
46. Cole MJ, Unemo M, Hoffmann S, et al. The European gonococcal antimicrobial surveillance programme, 2009. Euro Surveill 2011, 16(42). Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19995.
47. EpiNorth Network A Co-operation Project for Communicable Disease Control in Northern Europe Available at: http://www.epinorth.org (Accessed: January 19, 2014), EpiNorth Network.